MSLN and neoplasm: The main targeted proteins for CAR-T cell-based treatments for HGSOC that are overexpressed in the tumor (e.g., hTERT, ERbB2, mesothelin, and MUC-1) [13] shows limited success due to the reduced number of targetable membrane antigens and their heterogeneous expression patterns, as well as difficulties in achieving effective concentrations of T cells at target tumor sites.